Legal & General Group Plc Invests $5.29 Million in TransMedics Group, Inc. $TMDX

Legal & General Group Plc acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 79,582 shares of the company’s stock, valued at approximately $5,286,000. Legal & General Group Plc owned about 0.23% of TransMedics Group as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Silvant Capital Management LLC acquired a new stake in shares of TransMedics Group in the second quarter valued at about $26,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the third quarter worth about $29,000. North Star Investment Management Corp. purchased a new stake in TransMedics Group during the 1st quarter valued at about $30,000. Ascentis Independent Advisors purchased a new stake in TransMedics Group during the 1st quarter valued at about $30,000. Finally, Allworth Financial LP raised its holdings in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. UBS Group lowered their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Stifel Nicolaus upped their target price on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 target price on shares of TransMedics Group in a research note on Tuesday, June 30th. Finally, Needham & Company LLC lowered their price target on shares of TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Hold” and a consensus target price of $124.18.

TransMedics Group Stock Performance

Shares of TMDX opened at $86.98 on Friday. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The stock has a market capitalization of $3.01 billion, a PE ratio of 22.36 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The stock has a 50-day simple moving average of $79.71 and a 200-day simple moving average of $92.23.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm’s quarterly revenue was up 20.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.92 earnings per share. On average, analysts predict that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.